Senior M&A experts confirmed are
Bagrin Angelov is an M&A Executive Director in the Investment Banking division of China International Capital Corporation Limited (CICC) based in Beijing, where he is exclusively dedicated to China outbound M&A situations. Mr. Angelov has profound experience in supporting private multinational corporations and state owed enterprises with their cross-border M&A undertakings. To date he has advised on 100+ M&A deals globally (both in emerging and developed markets such as UK, USA, Germany, and Australia), with a combined transaction value of some US$100bn. Prior to CICC Mr. Angelov worked in the Investment Banking divisions of Barclays, ABN AMRO, The Royal Bank of Scotland, and a Middle Eastern SWF.
Mr. Bao Yi is the founder and chairman of Cedarlake Capital, a global investment platform focused on cross-border synergies, partnering with industry and financial leaders both within and outside China. Cedarlake Capital invests in leading enterprises and projects with clear synergy and prospect. By connecting major economies and markets, Cedarlake Capital helps to comprehensively upgrade the relevant industries, technologies and consumer sector in China. Cedarlake Capital currently manages a series of funds with a total amount over RMB10.0 billion. It is headquartered in Hong Kong and has offices in Shanghai and Frankfurt.
Mr. Bao possesses about 20 years of experience in the areas of investment, financing and capital markets in the US, Hong Kong and Mainland China. He is a well-respected advisor to leading Chinese businesses for both inbound and outbound financings, investments, acquisitions and restructurings.
Before founding Cerdarlake Capital, Mr. Bao was a managing director of Morgan Stanley Asia and a member of its China Management Committee. Mr. Bao was CEO of Morgan Stanley Huaxin Securities, Morgan Stanley’s China securities business. Prior to Morgan Stanley, Mr. Bao worked for world leading advisory firms Lazard and Deloitte Consulting.
Mr. Bao is Vice Chairman of Zhejiang Association of Overseas Chinese Entrepreneurs,Vice Chairman of Zhejiang Enterprise Economic Development Committee, and a member of Shanghai Youth Federation. Mr. Bao holds an MBA degree from the Wharton Business School at the University of Pennsylvania. He is recognized as a top financial expert in the Pudong New Area 100-Talent Program.
Tim Burroughs is managing editor of Asian Venture Capital Journal, having joined the publication in May 2011. He is responsible for all editorial content put out under the AVCJ brand, including Asian Venture Capital Journal, AVCJtv, AVCJ Awards and AVCJ.com. Tim previously spent five years at China Economic Review, serving as editor-in-chief and then editorial director. Located in Greater China since 2003, during which time he has lived in Beijing, Qingdao and Hong Kong, Tim has been a China-based contributor for publications including The Sunday Times, Sunday Telegraph, BBC and China Daily. Prior to moving to China, he trained and worked as a journalist in the UK. He was honored at the Society of Publishers in Asia awards in 2007, 2008 and 2010, and at the State Street Institutional Press Awards - Asia in 2012.
Mr. Eddie Chen's career path crosses numerous sectors and he has taken positions as the IT executive, diplomat, senior government official and private equity investor. He has been posted in the USA, Sweden, France and China.
Mr. Chen is currently the Managing Director and Head of China/Asia for EURAZEO S.E. EURAZEO is a leading French private equity company with 140 years in existence and a size of 16.5 billion Euro PE fund. Mr. Chen has engaged in major investment projects such as Accor, Asmodee, IES, Colisee, Fintrax, Worldstrides, etc.
Before EURAZEO, he was the Vice President for INVEST SWEDEN AGENCY - a Swedish government agency. Responsible for Greater China, he had initiated and established a profound Sino-Swedish bilateral investment cooperation. He completed over 200 Chinese investments to Sweden and vice versa. He is a well-known pioneer in both Europe and China in the Foreign-Direct-Investment field.
Before the Swedish government, he worked for UNITED NATIONS DEVELOPMENT PROGRAMME (UNDP) in New York. He was the Chief of the Information Technology Group, with the responsibility for all IT strategy and operations for the UN offices in 150 countries as well as led many IT projects for developing countries in all the continents. He had received recognitions from the UN CIO Conference (Chief Information Officer) in 1999.
Mr. Chen received a MS degree from New York University; and BS degree in Computer Science from Eastern Michigan University (USA) and Fudan University (China).
Li Chen is a partner in Shearman & Sterling’s M&A Group and has extensive experience in mergers and acquisitions. She represents major companies, private equity firms and sovereign wealth funds in public and private acquisitions and dispositions, as well as financings and other corporate transactions, with a particular focus on outbound acquisitions and investments by Chinese buyers.
Brian Chi is a Managing Director at Blackstone, focusing on private equity investments in Greater China. Before joining Blackstone, Mr. Chi was a Vice President at Morgan Stanley Private Equity Asia responsible for private equity investments in China. Before joining Morgan Stanley, Mr. Chi worked in the Mergers & Acquisitions Group at Citi Investment Banking Division in New York. Mr. Chi received a B.A. in Economics and Math from Brandeis University, where he graduated summa cum laude, and an M.B.A. from Harvard Business School.
Bennett Cohen is an innovation leader with over a decade of experience in startups, strategy and investing. Over the past few years Bennett established Shell's venture capital office in San Francisco and has invested in several startups and VC funds in Silicon Valley and Asia transforming the energy and transportation industries. Prior to Shell, Bennett served as Special Aide to Amory Lovins at Rocky Mountain Institute and was a Business Development Director at CPower—a demand response startup acquired by Constellation. Bennett is a Kauffman Fellow, serves on several boards, and is playing a key role in establishing Shell's venture capital arm in China.
Stephen Dai is Investment Director at Legend Holdings, tracking for control and significant minority investment opportunities in consumer and service sectors. Prior to that, Mr. Dai was a Director at Olympus Capital Asia, a pan-Asian private equity firm as well as Centurion Investment Management. Mr. Dai started his career in Ernest & Young and holds MBA and Bachelor of Finance from University of Hong Kong.
Ms Shengyan Fan joined China Everbright Limited in 2009 and is a Managing Director of the Merger & Acquisition Department. She also serves as a Managing Partner of the CEL Catalyst China Israel Fund and a member of the investment committee of the CEL Global Investment Fund and the CEL Catalyst China Israel Fund.
Ms. Fan has over 17 years’ experience in direct investment, capital raising and investment banking serving corporate clients in Greater China region as well as multinationals. Prior to joining CEL, Ms. Fan has held various positions with increasing responsibility at multinational investment banks.
Ms. Fan holds a BA and a BS from Tsinghua University and an MA from the University of Oxford.
John Gray is a Partner at Finsbury, the global leader in M&A communications, where he leads the firm’s merger and FDI clearance work on cases under UK and EU jurisdiction. Over the last decade he has advised on the political, regulatory and broader public affairs aspects of many of the highest profile domestic and cross-border M&A situations, including significant outbound Asian FDI. Recent work includes advising SoftBank Group Corp. on the USD 31bn acquisition of ARM Holdings plc, China Resources Gas Group Limited on their interest in the UK gas distribution business of National Grid plc, and Takeda Pharmaceutical Company Limited on the proposed USD 62bn acquisition of Shire plc. Prior to joining Finsbury in 2006, Mr. Gray spent six years working as a senior aide to a UK Member of Parliament. Educated at the University of Leeds, Mr. Gray holds a degree in History and a Masters degree in International Political Economy.
Amy oversees the firm’s quickly expanding emerging tech portfolios. She builds Hemi’s mission via developing a connected network of industry leaders and disruptive founders. She focuses her effort to help portfolio companies develop growth strategy and help with corporate investors building innovations. Prior to founding Hemi, she was the first General Manager of Evernote China, where she grew the user base to 20 million in four years. She also served as a growth advisor to Udacity, Robinhood and a handful of scaling tech companies. Fast Company named Amy among its “Most Creative People of 2015”, and “40 under 40 of 2018” by Silicon Valley Business Journal. She holds an MBA from Stanford. She spends her free time hiking across bay area, playing tennis and has run marathons on three continents.
Ashley He currently holds the position of Senior Investment Director at Ctrip.com, spearheading the investments in Flight, Travel Tech, and in emerging markets. Prior to that, Ms. He was with Sailing Capital, a $2bn Private Equity / Venture Capital based in Hong Kong and leading the investment practice in TMT space including Sensetime, Lyft, Didi Dache, etc. Ms. He started her career in investment banking and holds a BBA from University of Hong Kong.
Patricia Heiberger is Asia Pacific Managing Editor of Mergermarket and Dealreporter, global newswires for advisors, corporates, and buysiders. She has been a mergers and acquisitions journalist for more than a decade, and before that was an investigative and general finance reporter in her native Philippines. Based in Hong Kong, she now covers China M&A, private equity buyouts, and crossborder M&A. She previously covered Southeast Asia private equity and consumer deals out of Singapore.
Michael Hua, Director, New Business Development, is responsible for Johnson & Johnson Medical’s M&A, distribution, strategic alliances and divestitures in China. Some of the key deals Michael involved in at J&J including the $21 billion Synthes acquisition in 2012. Michael has an M&A and corporate strategy consulting background over 15 years covering mostly cross-border deals.
Mr. Jingkai Huang serves as the Chief Executive Officer at Shenzhen Tempus Logistics Holding Ltd., Chairman of the board of directors at Qianhai Tempus International Fine Wine Exchange and Vice Chairman of Tempus Holdings Limited, Executive Director of OTO Holdings Limited, and Director of Tempus Investment Holdings Ltd, Tempus Value Chain Limited, Tempus Holdings (Hong Kong) Limited and Shenzhen Tempus Logistics Holding Ltd. He also serves as standing Vice President of the Shenzhen Wine Industry Association, the Vice Chairman of Guangdong Provincial Alcohol Industry Association and the Vice Chairman of the China National Association for Liquor and Spirits Circulation. Mr. Huang served as the Chief Executive Officer at Tempus Holdings Limited since January 2015 until October 2016. Mr. Huang obtained the legal professional qualification certificate from the Ministry of Justice of the People’s Republic of China and has the qualification certificate of secretary of board of directors issued by the Shenzhen Stock Exchange. Mr Huang obtained Bachelor of Arts and Bachelor of Laws from Shenzhen University. Mr. Huang is also a graduate of the senior business administration seminar of Tsinghua University.
Frank Jin is an Executive Director within Morgan Stanley’s Mergers & Acquisitions Department based in Hong Kong
Frank has over 12 years of experience practicing M&A. Prior to joining Morgan Stanley, Frank worked within the Mergers & Acquisitions group at Standard Chartered and the law firm of Sullivan & Cromwell focusing on M&A transactions and leveraged finance in New York and Hong Kong. Frank is dual qualified as a New York lawyer and Hong Kong solicitor
Frank received a B.Sc. from the University of Toronto, in Biology and Commerce, and a J.D. from Harvard Law School
Sean King joined Park Strategies, a business advisory firm managed by former U.S. Senator Alfonse D'Amato, in 2006. His focus is Asia, generating business and supporting clients in the region. He also regularly comments on Asian current affairs.
Before joining Park Strategies, Mr. King spent five years at the United States Department of Commerce in Washington, DC, where he served as Senior Advisor for Asia in the U.S. & Foreign Commercial Service (USFCS). Before joining Commerce, Mr. King was based in Singapore for both PricewaterhouseCoopers (PwC) and Citibank. Mr. King also worked for the New York State Department of Economic Development, on whose behalf he led a 1997 trade mission to Taiwan.
Mr. King makes public speaking appearances, is a frequent on air television guest and his opinions and quotes have appeared in numerous publications. He has an MBA from the University of Notre Dame and an undergraduate degree from the American University in Washington, D.C. As part of his MBA, Mr. King did a summer internship for Citibank in Taipei. He is fluent in Swedish.
Mr. Tanguy Lesselin is the Chief Executive Officer at Finquest. Mr. Lesselin is a former consultant at The Boston Consulting Group and advised on M&A post-merger integration and JV projects in the pharma and aerospace industries. Prior to that, he was with CDI (now Mercer), advising Fortune 500 companies on organic and acquisition-based growth strategies. He has built Finquest to become the leading Big Data company for M&A in the mid-market space, helping global Private Equity, Multinational companies, and M&A advisors identify and source new M&A opportunities. Finquest has been named one of the Top 25 fintech companies in Asia, and now has offices in Singapore, Frankfurt, Hong Kong, Luxembourg and London. Mr. Lesselin has been featured on CNBC, Bloomberg, Reuters and is a frequent speaker on M&A, as well as on Big Data and AI applied to Corporate Finance. He graduated from HEC Paris with a Master of Science degree in Finance.
Alex Lin is the Strategy VP of Ping An Good Doctor, in charge of strategy, BD and globalization. Previously he held multiple positions in Sanofi, incl. Head of marketing and Head of strategy of Asia. He has deep experience in global leading consulting firm – Bain & Company. Mr. Lin hold MBA from INSEAD.
Samson Lo joined UBS in 2010 and is primarily responsible for M&A origination and execution in the Asia Pacific region, with a focus in Greater China across many industry sectors. From 2007-2010, Mr. Lo was a member of Merrill Lynch Asia Pacific's investment banking team for Hong Kong-based corporations. From 2000-2007, Mr. Lo was a member of Lehman Brothers' M&A group in New York City and led executions for transactions across many industry sectors.
Mr. Lo graduated magna cum laude from the University of Pennsylvania's Management & Technology Program, with joint undergraduate degrees from Wharton School and School of Engineering & Applied Sciences.
Raghu Narain brings over 20 years of experience in investment banking, corporate finance and economic policy advisory. Currently, Mr. Narain is Head of Investment Banking for Natixis, APAC with the responsibility to deliver M&A, Acquisition Financing, Strategic Equity, and DCM comprehensive solutions. Prior to Natixis, he was the Head of Sector Advisory and Global Industrials Group in RBS Asia. In his career, Mr. Narain has undertaken over 100 transactions by financing and advising US$75+ billion in completed deals for global companies. Mr. Narain has advised major global entities including Eurazeo, Continental Airlines, Fosun, GVK Infrastructure, Lafarge, MISC, MGM, Reliance, Shanghai Electric, Vedanta and UPS. Prior to working in Asia, he was at Bank of America in New York where he was a Director responsible for M&A and capital raising activities for the Global Transportation and Logistics Group. Mr. Narain began his investment banking career with Salomon Smith Barney / Citigroup in New York.
Mr. Narain has also worked at Bridgewater Associates as an Investment Associate and in the field of development finance at the Harvard Institute for International Development (HIID). He completed his Masters degree from Harvard University. He holds MPA, MBA and BA degrees from the United States. He is a member of the International Honor Society of Beta Gamma Sigma , and has often been highlighted and published in leading industry publications like CNBC, Institutional Investor China, The Asset, IFR, Marine Money, Drillers and Dealers Digest and The Daily Deal for his achievements in the field of financial services.
Christian Noske is Managing Director at Alliance Ventures, Renault-Nissan-Mitsubishi’s global investment organization, which manages corporate venture capital investment and open innovation, in support of the Alliance’s strategic objectives.
Co-located in Silicon Valley, Paris, Yokohama and Beijing, “Alliance Ventures” is $1 Billion venture capital fund operating for Renault-Nissan-Mitsubishi, the world’s leading automotive alliance. Launched in 2018, the fund targets technology and business model innovation in vehicle electrification, autonomous systems, car connectivity and new mobility services.
Christian joined the Alliance in January 2018 and leads the direct investment team with headquarter in Silicon Valley. Prior to joining, Christian was founding Partner at BMW i Ventures, BMW’s EUR 500 Mio. venture capital fund. He was on the board of many companies and led investments in companies that disrupt how consumers experience products and services.
Before working in Venture Capital, Christian was CFO for a digital agency that was acquired by WPP, and worked in Finance and Business Development for Robert Bosch GmbH in Germany and Asia.
David Russell is a Managing Director in the Shanghai office of Vermilion Partners, a China-focused M&A advisory firm. He joined Vermilion in 2009 and has focused on advising international clients on acquisitions and joint ventures in China in sectors including food & beverage, general industry and financial services, for clients such as Tate & Lyle, Imperial Brands, Home Retail Group, American Express, Coats Group and Unilever.
Prior to Vermilion, Mr. Russell was an Executive in Ernst & Young’s transaction advisory services team in London. He is a Chartered Accountant and holds a BA in Philosophy, Politics and Economics from the University of Oxford.
Gordon Shaw is co-founder and Managing Director of Baring Private Equity Asia, a pan-Asian private equity firm that advises on USD10 billion of assets under management. Mr. Shaw was previously Director at AIG Investment Corp (Asia) Ltd., as well as head of Equity Investments at Nan Shan Life Insurance in Taiwan. Prior to that, he was Senior Design Engineer at Schlumberger Technologies in San Jose, California. Mr. Shaw holds a BS in Electrical Engineering from Massachusetts Institute of Technology, and an MBA from Columbia University.Speaker bio coming soon
Zoe Shi joined KPMG Shanghai Transaction Services practice in 2007, focusing on advising multinational clients and PE houses in M&A transactions in China. Before joining transaction services, she worked in the auditing department in KPMG for three years. Ms. Shi was seconded to the PE group of transaction services in KPMG London office between October 2013 to March 2015.
Ms. Shi assisted her clients in providing financial due diligence in China market. She mainly focuses on providing due diligence to PE houses. Ms. Shi’s clients include Primavera, TPG, GIC, Goldman Sachs, MSPE, KKR etc. The sector she focuses includes consumer markets (retail and food & beverage), healthcare, real estate and education. By leveraging her past experiences, she is able to assist clients in understanding the sector-specific issues and client’s primary concerns in the transaction.
Ms. Shi’s recent experiences with PE houses include:
• Led buy-side financial due diligence for a leading PE house in potential investment in Mofang and Eggroll
• Led buy-side financial due diligence for GIC on its investment in Nova Group
• Led buy-side financial due diligence for Softbank on its potential investment a number of businesses under PingAn
• Led financial due diligence for a leading PE house for its potential investment in a leading brand in women’s dress which has more than 4000 stores in China
• Led a number of bolt-on acquisitions for ESR, a portfolio company of Warburg Pincus
• Led sell-side financial due diligence for a leading PE house for its potential divestment of its controlling shares in a manufacturer of condiment
• Led buy-side financial due diligence for Everbright Ashmore on its potential acquisition on a number of warehousing assets from Goodman
Dr. Staples received his medical training at Columbia University and his Post-Graduate training in Hawaii. Prior to joining UFH in 2016, Dr. Staples worked in the Middle East for 5 years, where he was recruited by The Cleveland Clinic as CEO of Sheik Khalifa Medical City, the largest hospital in the UAE. He subsequently served as the Group COO for the Al Noor Hospital Group, also based in the UAE, where he led a highly successful IPO on the London Stock Exchange. Prior to his time in the Middle East, Dr. Staples was Division President of North Asia for the Parkway Group, and was based in Shanghai. Dr. Staples has lived abroad, in Asia and the Middle East, for more than 20 years.
Simon Tsang is a managing director in the Valuation Advisory Services practice, and is based in the firm’s Shanghai office. Simon has more than 18 years of valuation, private equity investment and tax advisory experience in China and Hong Kong.
Simon is experienced in providing valuation advice and deliverables for private equity clients, for merger and acquisition transactions, and for financial reporting and initial public offerings (IPO) purposes. Simon has extensive experience in valuation, including purchase price allocation analysis, intangible asset valuation, financial derivatives valuation, financial modeling, business and equity interest valuation for acquisitions, divestitures, joint ventures, financing, restructuring, IPO, tax, go-private transactions and financial reporting.
Simon has advised clients in a wide variety of industries, including consumer products, life sciences and healthcare, manufacturing, technology and telecommunication, media and real estate. He has particular expertise in private equity portfolio valuation and has previously worked for a private equity firm, where he was responsible for deal execution and investment analysis. He has delivered presentations and training on valuation topics at various professional events. Before joining Duff & Phelps, Simon was a Partner in Deloitte Financial Advisory Services in China. Earlier in his career, he worked for a private equity firm as well as an international appraisal firm.
Jim Tsao is Chairman and Head of China and based in Permira's Shanghai office.
Prior to joining Permira, Jim was Partner, in charge of China, for Unitas Capital (formerly known as JP Morgan Partners Asia) for more than 10 years.
Before that, Jim had a distinguished career in the food and beverage industry. He was the CEO of the Hong Kong listed Lam Soon Group and Managing Director for Asia at Lion Nathan, the leading brewer conglomerate in Australia and New Zealand.
He holds an MBA from the University of Chicago, USA and is an Economics graduate of the National Taiwan University.
Dr. Wang has more than 10 years of business development and investment experience in biopharmaceutical industry. He is currently the managing partner of Advan Partners which is an investment advisory firm focusing on investing leading biotech and medtech companies in both North America and China. Before founding Advan Partners, David worked for Fosun Pharma as an investment director responsible for minority and M&A investment of biopharma companies in U.S.A and EU. From 2015-2018, he managed a portfolio over $300m USD. From 2014-2015, he served as an investment consultant at Canada’s largest independent healthcare focused advisory firm Bloom Burton & Co. From 1999-2005, he also worked at DIAO Group as an associate director responsible for oversea business development and market access of best-selling cardiovascular drugs. He also led commercialization of earliest biologic drugs in China such as EPO and Thymopentin. He completed cross-border investments of leading healthcare companies including Kite Pharma、iKang、Mindray、Gland Pharma、Tridem Pharma、Trillium Therapeutics, Arbutus Biopharma, and G1 Therapeutics. David holds MBA from University of Toronto, Ph.D.in Physiology from University of Saskatchewan, and completed post-doctoral training at Yale School of Medicine.
Dr. Jonathan Wang has close to 30 years of healthcare and life sciences experience, spanning investment, entrepreneurship, finance and research. He has been named one of the top 10 healthcare investors in China (ChinaVenture) and has invested in many successful companies, including ZAI Lab，ForteBIO, EA and Genewiz.
He is the founding partner and Senior Managing Director of OrbiMed Asia (OrbiMed is the world’s largest healthcare-dedicated investment firm). He is a HKEX Biotech Advisory Panel member and is a co-founder and former Chairman of BayHelix, a premier organization of Chinese healthcare business leaders.
Under the supervision of Eric Kandel, a Nobel Laureate, Jonathan obtained a Ph.D. in Neurobiology from Columbia University. He was rewarded the Howard Hughes Medical Institute (HHMI) Research Fellowship at Columbia. He also earned an MBA from Stanford University.
Steven Wang is former senior partner and investment committee member of CDH. He has more than 10 years of experience in the medical industry and healthcare investment and focuses exclusively on healthcare services, medical device and pharmaceutical sectors. Prior to CDH, Mr. Wang served at Avenue Capital, Lehman Brothers (London) and Becton Dickinson Group. Over the last ten years, Mr. Wang was responsible for transactions totaling more than 1.5 billion dollars, including mergers & acquisitions, restructuring of publicly listed companies, growth and early stage investments.
Some of Mr. Wang's representative deals include WuXi AppTec(603259), Kanghong Pharm (002773), KangNing Hospital (HK.02120), New Century Hospital(HK.01518), Yuwell (002223), New Eyes (430140), Linwha(835637), STA(832159), Poly(300630), Phamaron, Mindray, Angel’s Women and Children Hospital, Zhonghe Pharmaceutical, Kintor Pharmaceutical, Malo Clinic, Dr. Cuiyutao , General Healthy etc.
Yiqing Wang is China Editor of Mergermarket, a global news intelligence service for advisors, private equity firms and corporates. Ms. Wang is leading a team of dedicated journalists across mainland China to cover PE/VC fundraising, M&A deals, PE buyouts and China cross-border M&A intelligence. She has been an investigative M&A reporter and researcher since 2009, writing industry news ranging from healthcare, new energy and financial service, etc. Ms. Wang achieved her master degree of multilingual multicultural studies from New York University.
Mark Webster is a Partner at BDA Partners where he is Co-Head of the Shanghai office. He joined BDA in 2005, since when he has advised on sellside and buyside cross-border M&A for a variety of private equity and corporate clients including Carlyle, CITIC Capital, Kerry Group, Pfizer, and Sherwin-Williams. He previously worked for Standard Chartered Bank in Shanghai as a Vice President in the MNC division assisting global corporates such as BP, Syngenta and UPS with strategic, funding and operational matters. Prior to that, he worked at JPMorgan’s London office in their M&A department. He began his career at Arthur Andersen where he qualified as a Chartered Accountant (ACA) after having graduated from Oxford University.
Matthias Weissinger is a partner with Shearman & Sterling in Germany and is admitted to the German and New York bar. His practice focuses on domestic and cross-border restructurings and financings. He advises buyers and sellers on distressed M&A transactions and regularly represents national and international financial institutions, debt funds, sponsors and corporate borrowers on debt restructurings, out-of-court and in-court solutions, leveraged buyouts, unitranche financings, bank/bond financings, real estate financings and corporate lending for large- and mid-cap companies.
Matthias is recognized in the most recent editions of IFLR1000, Legal 500 Germany and in the "up and coming" category by both Chambers Global and Chambers Europe. He holds a German doctorate degree in law and an LLM degree from the University of Pennsylvania Law School.
Mr. Weng is Executive Vice President & Managing Director at China Financial International Investments Ltd. He brings a wealth of global M&A and investing experience, ranging from direct investments, private equity, hedge fund, asset management and investment banking. Mr. Weng had worked in global financial centers including New York, Toronto, Hong Kong, Shanghai, Beijing and Shenzhen.
Mr. Weng previously served as Director of M&A and Strategic Investments at China Vanke, a Fortune 500 company, as well as Investment Director at Mackenzie Investments, one of the largest institutional investors in Canada. Furthermore, Mr. Weng worked for global institutional investors including China Life Asset Management, UBS, and D. E. Shaw. In his career, Mr. Weng contributed valuable experience and expertise to the successful completion of landmark deals, including the USD$11.6bn acquisition of GLP, the largest M&A deal in Asia and the winner of the MergerMarket “2017 China M&A Deal of the Year Award”. In 2018, Mr. Weng served as one of the nine judges on the panel that evaluated and selected the MergerMarket “2018 China M&A Awards” winners.
Mr. Weng received his MBA from Harvard Business School and his Bachelor in Economics with Phi Beta Kappa, magna cum laude and Major Distinction from Yale University. In addition, Mr. Weng holds the CFA and FRM designations.
Outside of work, Mr. Weng taught finance and economics at Harvard University and Harvard Business School Executive Program. He is also an active member of Harvard and Yale alumni associations, and serves as an alumni interviewer for Yale University.
Sen joined JD Capital in 2016 and manages firm’s 320 million USD funds. He is responsible for souring, executing and managing firm’s outbound investments. Partnering with strategic and institutional investors, his team has closed 5 cross-border deals focusing on tourism and advanced manufacturing. He also serves on the boards of several portfolio companies, advising their business strategies and post-acquisition integrations.
Prior to JD Capital, he was an investment banker with Bank of America Merrill Lynch (BAML) in New York where he advised on a number of M&A deals. Mr. Zhang holds a Master degree from Rutgers University and a Bachelor of Science in Business Administration from the University of Arizona.
Yan Zhang is Director of Finance at Grab, Southeast Asia’s leading mobile technology company focused on bringing transport freedom and financial inclusion to millions of lives in more than 500 cities and towns across Southeast Asia. Ms. Zhang is responsible for company equity fundraising and strategic partnership in Greater China.
Ms. Zhang is a globally seasoned finance executive with 18 years of corporate finance, project finance, M&A and investment experience in US, China and Southeast Asia. Her experience covers industries such as fintech, automotive, energy and banking. She has proven track record of leading negotiations of cross-border M&A, fundraising for strategic projects and managing through operational complexities of JVs.
Ms. Zhang is a Chartered Financial Analyst. She holds an MBA from the Carnegie Mellon University Tepper Business School, an M.A. in International Studies from University of Denver and a B.A. from Renmin University in China.
Mr. Jason Zhao is the founding Managing Partner of CGF Capital Management and Founding member/Senior Advisor of China Post Life’s Alternative Investment Group. Jason focuses on Technology and Financial Services investments, and is experienced in cross border M&A, technology transfer and localisation, and specialises in bridging western management and market resources with Chinese companies. Jason also serves as an investment committee member and venture partner of several Chinese government and multinational company Chinese investment funds. He is frequently invited by the central government and national trade organizations to advise in market research and new policy discussions and drafting.
Prior to his investment career, Jason worked in US, Chinese and European multinational corporations such as Motorola, Sinopec, and Marconi, etc., and has held many senior management positions in functions ranging from product management, marketing to engineering. Jason hold MS and BS degrees in Engineering from US and Chinese universities and an MBA from the University of Chicago
Hao Zhou is a partner in Bain’s Hong Kong office. He leads the firm’s Mergers & Acquisitions practice in Greater China, and is a core member of Consumer Products, Retail and Financial Services practices.
Hao has over 10 years consulting and industry experience. He has extensive experiences working with corporate and financial investors across the whole M&A deal value chain, from diligences to post merger integration topics. He also leads major diligence and post-merger integration efforts for Chinese companies on outbound transactions.
Hao has also served clients in a wide range of industries with a focus on fast moving consumer goods, apparel, retail, industrial products and automotive.
Hao earned his MBA from INSEAD and graduated with both B.S. and MSc degree in Computer Science from Swiss Federal Institute of Technology in Zurich (ETH Zurich).